全文获取类型
收费全文 | 9241篇 |
免费 | 444篇 |
国内免费 | 88篇 |
专业分类
耳鼻咽喉 | 80篇 |
儿科学 | 201篇 |
妇产科学 | 72篇 |
基础医学 | 1018篇 |
口腔科学 | 124篇 |
临床医学 | 481篇 |
内科学 | 2727篇 |
皮肤病学 | 145篇 |
神经病学 | 711篇 |
特种医学 | 371篇 |
外科学 | 1657篇 |
综合类 | 41篇 |
预防医学 | 222篇 |
眼科学 | 160篇 |
药学 | 566篇 |
中国医学 | 11篇 |
肿瘤学 | 1186篇 |
出版年
2024年 | 14篇 |
2023年 | 71篇 |
2022年 | 127篇 |
2021年 | 257篇 |
2020年 | 137篇 |
2019年 | 178篇 |
2018年 | 227篇 |
2017年 | 191篇 |
2016年 | 234篇 |
2015年 | 250篇 |
2014年 | 313篇 |
2013年 | 363篇 |
2012年 | 600篇 |
2011年 | 628篇 |
2010年 | 337篇 |
2009年 | 360篇 |
2008年 | 616篇 |
2007年 | 668篇 |
2006年 | 642篇 |
2005年 | 648篇 |
2004年 | 611篇 |
2003年 | 576篇 |
2002年 | 576篇 |
2001年 | 93篇 |
2000年 | 81篇 |
1999年 | 98篇 |
1998年 | 139篇 |
1997年 | 98篇 |
1996年 | 81篇 |
1995年 | 86篇 |
1994年 | 67篇 |
1993年 | 44篇 |
1992年 | 53篇 |
1991年 | 42篇 |
1990年 | 37篇 |
1989年 | 36篇 |
1988年 | 27篇 |
1987年 | 25篇 |
1986年 | 12篇 |
1985年 | 11篇 |
1984年 | 11篇 |
1983年 | 14篇 |
1982年 | 17篇 |
1981年 | 9篇 |
1980年 | 7篇 |
1979年 | 10篇 |
1978年 | 7篇 |
1975年 | 6篇 |
1973年 | 7篇 |
1966年 | 4篇 |
排序方式: 共有9773条查询结果,搜索用时 15 毫秒
71.
The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma. 总被引:4,自引:0,他引:4
72.
Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma. 总被引:9,自引:0,他引:9
Shinji Yamamoto Yasuhiko Tomita Yoshihiko Hoshida Shuji Takiguchi Yoshiyuki Fujiwara Takushi Yasuda Masahiko Yano Shoji Nakamori Masato Sakon Morito Monden Katsuyuki Aozasa 《Journal of clinical oncology》2003,21(13):2537-2544
PURPOSE: Valosin-containing protein (VCP; also known as p97) was shown to be associated with antiapoptotic function and metastasis via activation of nuclear factor kappa-B signaling pathway. In this study, association of VCP expression with recurrence of gastric carcinoma (GC), in which lymphatic vessels are the main route of spread, was examined. PATIENTS AND METHODS: VCP expression in 330 patients with GC (242 males and 88 females) with ages ranging from 26 to 81 years (median, 60 years) was analyzed by immunohistochemistry, in which staining intensity in tumor cells was categorized as weaker (level 1) or equal to or stronger (level 2) than that in endothelial cells. RESULTS: Ninety-four (28.7%) patient cases showed level 1 and 233 patient cases (71.3%) showed level 2 VCP expression. Patients with level 2 expression showed higher rates of large tumor size (P <.0001), undifferentiated histologic subtype (P <.05), presence of vascular and lymphatic invasion (P <.0001 for both), presence of lymph node metastasis (P <.0001), deep tumor invasion (P <.0001), and poorer disease-free and overall survivals (P <.0001 for both) compared with those with level 1 VCP expression. Multivariate analysis revealed VCP expression level as an independent prognosticator for disease-free and overall survival. VCP level was an indicator for disease-free and overall survival in the early (pT1; P <.01 and P <.05, respectively) and advanced (pT2-4; P <.05 for both) group of pathologic tumor-node-metastasis system classification. CONCLUSION: The prognostic significance of VCP expression level in GC was demonstrated. 相似文献
73.
Tatsuro Tajiri Xueyuan Liu Patricia M Thompson Shinji Tanaka Sachiyo Suita Huaqing Zhao John M Maris George C Prendergast Michael D Hogarty 《Clinical cancer research》2003,9(9):3345-3355
PURPOSE: Amplification of the MYCN proto-oncogene is strongly correlated with poor outcome in neuroblastoma (NB), although deregulated MYCN is a potent inducer of apoptosis. BIN1 (2q14) encodes multiple isoforms of a Myc-interacting adaptor protein that has features of a tumor suppressor, including the ability to inhibit Myc-mediated cell transformation and to promote apoptosis. We hypothesized that BIN1 may function as a suppressor gene in NB, because Bin1 is highly expressed in neural tissues and binds the Myc Box motifs that are conserved in MycN. EXPERMENTAL DESIGN: Expression of MYCN, total BIN1, and BIN1 isoforms were determined in 56 primary NBs using the real-time PCR. Expression was correlated with biological and genetic features. To determine the functional significance of BIN1 expression we ectopically expressed BIN1 isoforms in NB cell lines with and without MYCN amplification, and assessed clonogenic growth. RESULTS: Four predominant BIN1 isoforms resulting from alternative splicing of exon 12A (a neural tissue-specific exon) and exon 13 (a Myc-binding domain encoding exon) were variably expressed in the 56 primary NBs. Expression of BIN1 was lower in: NBs with MYCN amplification (n = 10) compared with those without, P < 0.03; in International Neuroblastoma Risk Group high-risk NB (n = 19) compared with low- or intermediate-risk NB, P < 0.01; and in metastatic NB (n = 21) compared with localized NB, P < 0.06. BIN1 inactivation by deletion or genomic rearrangement was identified infrequently. Forced expression of BIN1 isoforms containing the Myc-binding domain (with or without exon 12A) inhibited colony formation in NB cell lines with MYCN amplification (P < 0.01) but not in those without. Forced expression of BIN1 isoforms with a MBD deletion did not inhibit colony formation in any cell line assessed. CONCLUSIONS: These data support that reduced BIN1 expression contributes to the malignant phenotype of childhood NB. As we reported previously, BIN1 may function to circumvent MycN-mediated apoptosis in NBs with MYCN amplification. 相似文献
74.
Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. 总被引:11,自引:0,他引:11
75.
Kiyoshi Ohara Hideo Tatsuzaki Hiroshi Fuji Shinji Sugahara Toshiyuki Okumura Eiichi Akaogi Masataka Onizuka Shigemi Ishikawa Kiyofumi Mitsui Yuji Itai 《Acta oncologica (Stockholm, Sweden)》1998,37(5):471-474
Patterns of radiologic response of 10 thymomas treated by preoperative radiotherapy (RT) (18-20 Gy/2 weeks) were determined in conjunction with histologic response. Changes in tumor volume were evaluated with CT scans obtained 5 to 36 days before and 14 to 24 days after the initiation of RT and before surgery. The extent of tumor volume reduction (TR) varied widely (40-78%), while the mean daily volume decrement expressed as a percentage of the pre-RT tumor volume correlated significantly with the pre-RT tumor volume. Histologically, the tumors, all of which were resected 17 to 33 days after RT initiation, generally consisted of predominant fibrous tissues, rare necrotic foci, and few epithelial cells. The TR did not correlate with pre-RT tumor volume, observation period, histologic subtype, or quantity of remaining epithelial cells. The TR of thymomas does not predict RT impact on tumor cells but does reflect the quantity of inherent tumor stroma. 相似文献
76.
Shinji Ohmori Yasuo Ohno Tadashi Makino Toshio Kashihara 《European journal of pharmaceutics and biopharmaceutics》2005,59(2):289-297
The purpose of this study was to apply an electronic nose system for evaluation of unpleasant odor in tablets containing L-cysteine, an unpleasant odor drug, and demonstrate the odor masking ability of thin-layer sugarless coated tablets, which we have newly developed, by both electronic nose system and sensory evaluations. We demonstrated the qualitative evaluation of the unpleasant odor using air as a reference indicator and the quantitative evaluation of the unpleasant odor using the distances between air and samples in the electronic nose system evaluation. The electronic nose system evaluation was positively and well-correlated with the sensory evaluation by volunteers. We suggest that the electronic nose system evaluation is appropriate as an alternative or a support method for sensory evaluation by volunteers. As the results of both electronic nose system and sensory evaluations, we demonstrated that the thin-layer sugarless coated tablets have excellent masking ability of the unpleasant odor, equivalent to that of sugar-coated tablets due to the dense coating layers. 相似文献
77.
78.
79.
Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. 总被引:4,自引:0,他引:4
Toshiya Chiba Koichi Tokuuye Yasushi Matsuzaki Shinji Sugahara Yoshimichi Chuganji Kenji Kagei Junichi Shoda Masaharu Hata Masato Abei Hiroshi Igaki Naomi Tanaka Yasuyuki Akine 《Clinical cancer research》2005,11(10):3799-3805
PURPOSE: We present results of patients with hepatocellular carcinoma (HCC) treated with proton beam therapy. EXPERIMENTAL DESIGN: We reviewed 162 patients having 192 HCCs treated from November 1985 to July 1998 by proton beam therapy with or without transarterial embolization and percutaneous ethanol injection. The patients in the present series were considered unsuitable for surgery for various reasons, including hepatic dysfunction, multiple tumors, recurrence after surgical resection, and concomitant illnesses. The median total dose of proton irradiation was 72 Gy in 16 fractions over 29 days. RESULTS: The overall survival rate for all of the 162 patients was 23.5% at 5 years. The local control rate at 5 years was 86.9% for all 192 tumors among the 162 patients. The degree of impairment of hepatic functions attributable to coexisting liver cirrhosis and the number of tumors in the liver significantly affected patient survival. For 50 patients having least impaired hepatic functions and a solitary tumor, the survival rate at 5 years was 53.5%. The patients had very few acute reactions to treatments and a few late sequelae during and after the treatments. CONCLUSIONS: Proton beam therapy for patients with HCC is effective, safe, well tolerable, and repeatable. It is the useful treatment mode for either cure or palliation for patients with HCC irrespective of tumor size, tumor location in the liver, insufficient feeding of the tumor with arteries, presence of vascular invasion, impaired hepatic functions, and coexisting intercurrent diseases. 相似文献
80.
Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. 总被引:3,自引:0,他引:3
Kenta Yoshiura Takashi Nakaoka Toshihide Nishishita Katsuaki Sato Akifumi Yamamoto Shinji Shimada Toshiaki Saida Yutaka Kawakami Tsuneo A Takahashi Hiroyuki Fukuda Shinobu Imajoh-Ohmi Naoki Oyaizu Naohide Yamashita 《Clinical cancer research》2005,11(22):8201-8207
Tumor-associated antigens are promising candidates as target molecules for immunotherapy and a wide variety of tumor-associated antigens have been discovered through the presence of serum antibodies in cancer patients. We previously conducted dendritic cell therapy on 10 malignant melanoma patients and shrinkage or disappearance of metastatic tumors with massive necrosis occurred in two patients. In this study, we found a 29-kDa protein against which antibody was elicited by dendritic cell therapy in one of the two patients. Matrix-assisted laser desorption ionization-time of flight/mass spectrometry analysis of the protein isolated by two-dimensional electrophoresis combined with Western blots revealed that the 29-kDa protein was carbonic anhydrase II (CA-II). Immunohistochemistry of the tumors and normal tissues showed that CA-II was expressed in the tumor vessel but not in normal vessel endothelium. CA-II expression in tumor endothelium was observed as well in other cancers including esophageal, renal, and lung cancers. In an in vitro angiogenesis model, CA-II expression of normal human vein endothelial cells was significantly up-regulated when cells were cultured in the acidic and hypoxic conditions indicative of a tumor environment. These findings suggest that CA-II is a tumor vessel endothelium-associated antigen in melanoma and other cancers, and elicitation of serum anti-CA-II antibody by dendritic cell therapy may be associated with good clinical outcome including tumor reduction. 相似文献